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Background
In systemic amyloidosis, disease is caused by extracellu-
lar accumulation of amyloid fibrils which, unlike other
interstitial debris, are not cleared and which disrupt tis-
sue structure and function. Direct removal of amyloid
deposits is required to preserve and possibly restore tis-
sue and organ function. We are targeting serum amyloid
P component (SAP) for this purpose. SAP normal
plasma protein is a normal plasma protein which binds
to all amyloid fibrils and is thus always present in all
human amyloid deposits. Administration of hexanoyl bis
(D–proline) (CPHPC) swiftly depletes circulating SAP
but leaves some SAP in amyloid deposits as an amyloid-
specific antigen target. In human SAP transgenic mice
with systemic AA amyloidosis, CPHPC treatment, to
deplete human SAP from the plasma, followed by a single
dose of anti-human SAP antibodies produced swift,
almost complete, clearance of visceral amyloid (Bodin
et al. Nature, 2010;468:93-7). In a mouse SAA transgenic
systemic amyloidosis model, which uniquely includes car-
diac amyloid, a second dose of anti–SAP antibody, after
the first dose had eliminated massive liver and spleen
deposits, significantly removed amyloid from the heart
(Simons et al. Proc Natl Acad Sci USA. 2013;110:16115-
20). Amyloid clearance by anti-SAP antibody required
classical complement pathway activation and macro-
phages. Amyloid destruction was mediated by multinu-
cleated giant cells (MGCs), formed by macrophage
fusion. MGCs have abundant surface membrane ruffles,
enabling the engulfment of very large complement opso-
nised amyloid targets which were then swiftly destroyed
within phagolysosomes. Amyloid clearance was maximal
by 14 days. No ill effects were detected. After licensing
this new treatment in February 2009, GlaxoSmithKline
(GSK) fully humanised our optimal mouse monoclonal
anti-SAP antibody and prepared for the first in human
clinical study that started in June 2013. We have lately
reported that a single dose of humanized monoclonal
anti-SAP antibody, following depletion of circulating SAP
by CPHPC, substantially reduced the amyloid load, espe-
cially from the liver, in patients with systemic AL, AA
and AApoAI amyloidosis, (Richards et al, New Engl
J Med, July 15 2015; DOI: 10.1056/NEJMoa1504942).
Methods
GSK’s phase I study of the obligate therapeutic partnership
of CPHPC and anti–SAP antibody in patients with sys-
temic amyloidosis is ongoing (http://www.clinicaltrials.
gov/ct2/show/NCT01777243?term=amyloid+gsk&rank=2).
The first patients with ATTR are about to be treated.
Results
Efficacy in amyloid removal requires a sufficient dose of
antibody and is associated with a transient early acute
phase response of CRP and SAA, transient early mild
neutrophilia and then notable depletion of plasma C3
and a less marked fall in C4 and CH50 (Richards et al,
New Engl J Med, July 15 2015). Amyloid removal has
not been associated with detectable additional organ
dysfunction. On the contrary, abnormal liver function
tests improved following clearance of hepatic amyloid
and the treatment has so far been generally well toler-
ated (Richards et al, New Engl J Med, July 15 2015).
Conclusions
Treatment with CPHPC and anti–SAP antibody pro-
motes amyloid removal in all types of systemic amyloi-
dosis tested so far. Efficacy in ATTR, in which hepatic
amyloid is never present and the main organs involved
are the nerves and heart, will be of considerable interest.
The Phase I study of CPHPC and anti-SAP antibody is
funded by GlaxoSmithKline.
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